Gai Zhibo, Visentin Michele, Hiller Christian, Krajnc Evelin, Li Tongzhou, Zhen Junhui, Kullak-Ublick Gerd A
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Department of Pathology, School of Medicine, Shandong University, Jinan, China.
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5573-80. doi: 10.1128/AAC.00907-16. Print 2016 Sep.
Nephrotoxicity is a relevant limitation of gentamicin, and obese patients have an increased risk for gentamicin-induced kidney injury. This damage is thought to depend on the accumulation of the drug in the renal cortex. Obese rats showed substantially higher levels of gentamicin in the kidney than did lean animals. This study characterized the role of organic cation transporters (OCTs) in gentamicin transport and elucidated their possible contribution in the increased renal accumulation of gentamicin in obesity. The mRNA and protein expression levels of the organic cation transporters Oct2 (Slc22a2) and Oct3 (Slc22a3) were increased in kidney samples from obese mice fed a high-fat diet. Similarly, OCT2 (∼2-fold) and OCT3 (∼3-fold) showed increased protein expression in the kidneys of obese patients compared with those of nonobese individuals. Using HEK293 cells overexpressing the different OCTs, human OCT2 was found to transport [(3)H]gentamicin with unique sigmoidal kinetics typical of homotropic positive cooperativity (autoactivation). In mouse primary proximal tubular cells, [(3)H]gentamicin uptake was reduced by approximately 40% when the cells were coincubated with the OCT2 substrate metformin. The basolateral localization of OCT2 suggests that gentamicin can enter proximal tubular cells from the blood side, probably as part of a slow tubular secretion process that may influence intracellular drug concentrations and exposure time. Increased expression of OCT2 may explain the higher accumulation of gentamicin, thereby conferring an increased risk of renal toxicity in obese patients.
肾毒性是庆大霉素的一个相关局限性,肥胖患者发生庆大霉素诱导的肾损伤的风险增加。这种损伤被认为取决于药物在肾皮质中的蓄积。肥胖大鼠肾脏中的庆大霉素水平显著高于瘦鼠。本研究确定了有机阳离子转运体(OCTs)在庆大霉素转运中的作用,并阐明了它们在肥胖患者中庆大霉素肾脏蓄积增加方面可能的作用。在喂食高脂饮食的肥胖小鼠的肾脏样本中,有机阳离子转运体Oct2(Slc22a2)和Oct3(Slc22a3)的mRNA和蛋白表达水平升高。同样,与非肥胖个体相比,肥胖患者肾脏中的OCT2(约2倍)和OCT3(约3倍)蛋白表达增加。使用过表达不同OCTs的HEK293细胞,发现人OCT2以典型的同向正协同性(自激活)的独特S形动力学转运[³H]庆大霉素。在小鼠原代近端肾小管细胞中,当细胞与OCT2底物二甲双胍共同孵育时,[³H]庆大霉素摄取减少约40%。OCT2的基底外侧定位表明庆大霉素可能从血液侧进入近端肾小管细胞,这可能是缓慢肾小管分泌过程的一部分,可能会影响细胞内药物浓度和暴露时间。OCT2表达增加可能解释了庆大霉素更高的蓄积,从而使肥胖患者发生肾毒性的风险增加。